A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

NCT07750041 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Advanced or Metastatic Colorectal Cancer

Interventions

DRUG: SYS6090 (Fixed Dose Level A) + bevacizumab
DRUG: SYS6090 (Fixed Dose Level B ) + bevacizumab
DRUG: SYS6090 RP2D + bevacizumab +mFOLFOX6
DRUG: SYS6090 RP2D + bevacizumab
DRUG: Regorafenib
DRUG: SYS6090 PR2D+ bevacizumab + FOLFOXIRI
DRUG: bevacizumab + FOLFOXIRI

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.